» Articles » PMID: 34659565

MiR-338-5p-ZEB2 Axis in Diagnostic, Therapeutic Predictive and Prognostic Value of Gastric Cancer

Overview
Journal J Cancer
Specialty Oncology
Date 2021 Oct 18
PMID 34659565
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

MiRNAs have been widely reported to be involved in the occurrence and development of cancers. So far, some studies have revealed that miR-338-5p has the functions of tumorigenesis and tumor suppression. However, the role of miR-338-5p in the pathogenesis, progression and treatment of gastric cancer (GC) has not been reported. MiRNAs microarray analysis showed for the first time that miR-338-5p was significantly lower-expression in cisplin-resistant GC cells SGC7901/DDP, and cell viability assay and flow cytometry confirmed that overexpression of miR-338-5p could significantly increase cisplatin-sensitivity of SGC7901/DDP and BGC823 cells. Subsequently, we found that the expression of miR-338-5p in postoperative cancer tissues of GC patients was also significantly lower than the corresponding paracancer tissues. The expression of miR-338-5p in peripheral blood serum of GC patients is generally lower than that of healthy people. Moreover, the low expression of miR-338-5p in the cancer tissues and serum of GC patients was closely associated with larger tumor volume, lymph node metastasis, later stage, and even poorer survival, which was confirmed by close 5-year cases follow-up. ZEB2, as a predictive target of miR-338-5p, its expression was negatively regulated by miR-338-5p and can promote cisplatin-resistance in SGC7901/DDP and BGC823 cells. The expression of ZEB2 in cisplatin-resistant SGC7901/DDP cells and GC tissues were significantly higher than SGC7901 cells and paracancer tissues, respectively. Moreover, the expression of ZEB2 in tumor tissues was negatively correlated with miR-338-5p in tumor tissues and peripheral blood serum of GC patients, and the abnormally high expression of ZEB2 in prospective case studies is positively related with more serious clinical pathology and worse survival. More meaningfully, in a retrospective case study, we found that high ZEB2 expression predicts worse clinical efficacy of platinum chemotherapy. Thus, miR-338-5p-ZEB2 axis have novel diagnostic, therapeutic predictive, and prognostic value in GC patients.

Citing Articles

MiR-338-5p, a novel metastasis-related miRNA, inhibits triple-negative breast cancer progression by targeting the ETS1/NOTCH1 axis.

Chen W, Ye Q, Wu H, Wu Z, Lan Y, Fang Z Heliyon. 2024; 10(15):e34949.

PMID: 39157351 PMC: 11327603. DOI: 10.1016/j.heliyon.2024.e34949.


Hsa_circ_0001278 Facilitates Colorectal Cancer Progression Sponging miR-338-5p and Regulating AMOTL1 Expression.

Ge H, Yan Y, Wang H, Bian J, Deng Z, Su X Comb Chem High Throughput Screen. 2023; 28(1):99-109.

PMID: 38018210 DOI: 10.2174/0113862073265207231108052536.


Role of Some microRNA/ADAM Proteins Axes in Gastrointestinal Cancers as a Novel Biomarkers and Potential Therapeutic Targets-A Review.

Kalita A, Sikora-Skrabaka M, Nowakowska-Zajdel E Curr Issues Mol Biol. 2023; 45(4):2917-2936.

PMID: 37185715 PMC: 10136553. DOI: 10.3390/cimb45040191.

References
1.
Geng D, Kan X, Zhang W . Effect of ZEB2 silencing on cisplatin resistance in gastric cancer. Eur Rev Med Pharmacol Sci. 2017; 21(8):1746-1752. View

2.
Xing Z, Yu L, Li X, Su X . Anticancer bioactive peptide-3 inhibits human gastric cancer growth by targeting miR-338-5p. Cell Biosci. 2016; 6:53. PMC: 5034486. DOI: 10.1186/s13578-016-0112-8. View

3.
Niinuma S, Tomari Y . ATP is dispensable for both miRNA- and Smaug-mediated deadenylation reactions. RNA. 2017; 23(6):866-871. PMC: 5435859. DOI: 10.1261/rna.060764.117. View

4.
Shao Y, Guo X, Zhao L, Shen Y, Niu C, Wei W . A Functional Variant of the miR-15 Family Is Associated with a Decreased Risk of Esophageal Squamous Cell Carcinoma. DNA Cell Biol. 2020; 39(9):1583-1594. DOI: 10.1089/dna.2020.5606. View

5.
Mohr A, Mott J . Overview of microRNA biology. Semin Liver Dis. 2015; 35(1):3-11. PMC: 4797991. DOI: 10.1055/s-0034-1397344. View